Observational studyThe Journal of clinical investigation2021
Parkinson disease among patients treated for benign prostatic hyperplasia with α1 adrenergic receptor antagonists.
Observational study in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Exposure to Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease: A Meta-Analysis.Journal of Parkinson's disease · 2024Pooled it
- A pilot to assess target engagement of terazosin in Parkinson's disease.Parkinsonism & related disorders · 2022Trial
- Glycolysis-enhancing αAlzheimer's research & therapy · 2026Article
- APOE4 reduces hippocampal expression of phosphoglycerate kinase 1 and sodium potassium pump to enhance seizure susceptibility in mice.Neurobiology of disease · 2026Article
- A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults.Journal of Parkinson's disease · 2025Article
- Neuroprotection in Parkinson Disease.Neurology and therapy · 2025Review
- αPharmaceuticals (Basel, Switzerland) · 2025Review
- Modulation of neuronal α1-adrenergic receptor reduces tauopathy and neuroinflammation by inhibiting the STING/NF-κB/NLRP3 signaling pathway in Alzheimer's disease mice.Journal of neuroinflammation · 2025Article
- Phosphoglycerate kinase is a central leverage point in Parkinson's disease-driven neuronal metabolic deficits.Science advances · 2024Article
- Update: Protective and risk factors for Parkinson disease.Parkinsonism & related disorders · 2024Review
- Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men.Neurology · 2024Article
- Risk of Parkinson's disease among users of alpha-adrenergic receptor antagonists: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2024Article
- A model for stimulation of enzyme activity by a competitive inhibitor based on the interaction of terazosin and phosphoglycerate kinase 1.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Observational
- Glycolysis-enhancing αNPJ Parkinson's disease · 2023Article
- αInternational journal of molecular sciences · 2023Review
- Clinical Trial Highlights: Modulators of Mitochondrial Function.Journal of Parkinson's disease · 2023Article
- Use of Glycolysis-Enhancing Drugs and Risk of Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2022Observational
- LncRNA NEAT1 facilitates glioma progression via stabilizing PGK1.Journal of translational medicine · 2022Article
- Parkinson disease risks: correctly identifying environmental factors for a chronic disease.The Journal of clinical investigation · 2021Article
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDRecently the α1 adrenergic receptor antagonist terazosin was shown to activate PGK1, a possible target for the mitochondrial deficits in Parkinson disease related to its function as the initial enzyme in ATP synthesis during glycolysis. An epidemiological study of terazosin users showed a lower incidence of Parkinson disease when compared with users of tamsulosin, an α1 adrenergic receptor antagonist of a different class that does not activate PGK1. However, prior research on tamsulosin has suggested that it may in fact potentiate neurodegeneration, raising the question of whether it is an appropriate control group.METHODSTo address this question, we undertook an epidemiological study on Parkinson disease occurrence rate in 113,450 individuals from the United States with 5 or more years of follow-up. Patients were classified as tamsulosin users (n = 45,380), terazosin/alfuzosin/doxazosin users (n = 22,690), or controls matched for age, sex, and Charlson comorbidity index score (n = 45,380).RESULTSIncidence of Parkinson disease in tamsulosin users was 1.53%, which was significantly higher than that in both terazosin/alfuzosin/doxazosin users (1.10%, P < 0.0001) and matched controls (1.01%, P < 0.0001). Terazosin/alfuzosin/doxazosin users did not differ in Parkinson disease risk from matched controls (P = 0.29).CONCLUSIONThese results suggest that zosins may not confer a protective effect against Parkinson disease, but rather that tamsulosin may in some way potentiate Parkinson disease progression.FUNDINGThis work was supported by Cerevel Therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.